Search

Your search keyword '"R. Grandez"' showing total 2 results
Start Over Author "R. Grandez" Topic in patient
2 results on '"R. Grandez"'

1. P-50 Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study

Author

F. Rivera Herrero, V. Alonso Orduña, C. Grávalos Castro, E. Mata Velasco, M.T. Delgado Urena, R. Grandez, M.J. Safont Aguilera, Marta Llanos, Enrique Aranda, P. García-Alfonso, A. Illán Varella, J. J. Reina Zoilo, I. Fernandez Rañada, J. Rodriguez-Pascual, Mireia Moreno, J. Mendez, P. Pimentel, C. Castañón, Beatriz García-Paredes, R. Afonso, I. Siso, and A.M. López Muñoz

Subjects
Oncology, medicine.medical_specialty, Refractory, business.industry, Colorectal cancer, Internal medicine, Medicine, In patient, Hematology, business, medicine.disease, Real life setting
Published
2021

2. SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus

Author

Imanol Arozarena, Maria Luisa Gomez-Dorronsoro, Saioa Goñi, M. Benavent, A. De Jesus-Acosta, V. Alonso, G. Crespo Herrero, V. Arrazubi Arrula, Marta Llanos, Ana Custodio, Marina Baretti, Iranzu González-Borja, B. López de San Vicente, C. López, R. Grandez, M.C. Riesco Martínez, A. Viudez, A. Carmona Bayonas, and P. Jiménez-Fonseca

Subjects
Oncology, medicine.medical_specialty, Prognostic factor, Everolimus, Clinical variables, business.industry, O-6-methylguanine-DNA methyltransferase, Hematology, Prognostic score, Internal medicine, Distribution pattern, medicine, Immunohistochemistry, In patient, business, medicine.drug
Abstract

Background Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET. The present multicenter project is retrospectively analyzing the predictive/prognosis role of MGMT, NDRG-1 and PHLDA-3 in patients with advanced PanNET treated CAPTEM or everolimus. Methods IHC nuclear staining for MGMT and PHLDA-3 is being scored as 0, 1-5%, 6-50% and ≥ 51%. For NDRG-1, we are using a cytoplasmic score from 0 to 3 based on staining intensity and distribution pattern (patched or diffuse). Results Until now, clinical and samples data from 96 patients (110 samples) has been collected ad are currently being analyzed. Based on our previous results, we will develop an imunohistochemistry prognostic score (IPS, score from 0 to 4) and try to correlate it with clinical variables collected in our database. Conclusions As we described previously in operated PanNET, we will try to describe the potential role of IPS as predictive/ prognostic factor in advanced PanNET. More mature results of this work will be presented during 2019 ESMO Congress. Legal entity responsible for the study Navarrabiomed Biomedical Research Center, Pamplona, Navarra, Spain. Funding GETNE. Disclosure All authors have declared no conflicts of interest.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results